These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1367 related articles for article (PubMed ID: 29384031)

  • 1. Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act.
    Spivey CA; Wang J; Qiao Y; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
    J Manag Care Spec Pharm; 2018 Feb; 24(2):97-107. PubMed ID: 29384031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.
    Wang J; Qiao Y; Shih YC; Jarrett-Jamison J; Spivey CA; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
    J Manag Care Spec Pharm; 2015 Nov; 21(11):993-1003. PubMed ID: 26521111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and ethnic disparities in meeting Part D MTM eligibility criteria among the non-Medicare population.
    Wang J; Brown LM; Hong SH
    J Am Pharm Assoc (2003); 2012; 52(5):e87-96. PubMed ID: 23023863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and ethnic disparities in meeting MTM eligibility criteria among patients with asthma.
    Lu D; Qiao Y; Johnson KC; Wang J
    J Asthma; 2017 Jun; 54(5):504-513. PubMed ID: 27676212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria.
    Wang J; Qiao Y; Tina Shih YC; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC
    Res Social Adm Pharm; 2014; 10(1):106-25. PubMed ID: 23759673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.
    Spivey CA; Qiao Y; Wang J; Shih YT; Wan JY; Dagogo-Jack S; Cushman WC; Hines LE; Chisholm-Burns MA
    J Am Geriatr Soc; 2019 Mar; 67(3):581-587. PubMed ID: 30674080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population.
    Wang J; Surbhi S; Zhang Z; Spivey CA; Chisholm-Burns M
    Res Social Adm Pharm; 2014; 10(6):904-917. PubMed ID: 25458405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.
    Qiao Y; Spivey CA; Wang J; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns MA
    Inquiry; 2018; 55():46958018795749. PubMed ID: 30175638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia.
    Chisholm-Burns MA; Spivey CA; Tsang CCS; Wang J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):688-699. PubMed ID: 35621720
    [No Abstract]   [Full Text] [Related]  

  • 10. Disparity implications of Medicare eligibility criteria for medication therapy management services.
    Wang J; Mullins CD; Brown LM; Shih YC; Dagogo-Jack S; Hong SH; Cushman WC
    Health Serv Res; 2010 Aug; 45(4):1061-82. PubMed ID: 20500223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Historical trend of disparity implications of Medicare MTM eligibility criteria.
    Wang J; Qiao Y
    Res Social Adm Pharm; 2013; 9(6):758-69. PubMed ID: 23062785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solving racial/ethnic disparities associated with Medicare Part D Star Ratings.
    Dong X; Tsang CCS; Browning JA; Sim Y; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Wang J
    Curr Med Res Opin; 2023 Jul; 39(7):963-971. PubMed ID: 37219396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.
    Browning JA; Tsang CCS; Zeng R; Dong X; Garuccio J; Wan JY; Chisholm-Burns MA; Finch CK; Tsao JW; Wang J
    Curr Med Res Opin; 2022 Oct; 38(10):1715-1725. PubMed ID: 35852087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia.
    Steve Tsang CC; Wan JY; Chisholm-Burns MA; Li M; Dagogo-Jack S; Cushman WC; Hines LE; Wang J
    Res Social Adm Pharm; 2021 Aug; 17(8):1469-1477. PubMed ID: 33272859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparity Implications of Proposed 2015 Medicare Eligibility Criteria for Medication Therapy Management Services.
    Wang J; Qiao Y; Spivey CA; Li C; Clark C; Deng Y; Liu F; Tillman J; Chisholm-Burns M
    J Pharm Health Serv Res; 2016 Dec; 7(4):209-215. PubMed ID: 28025599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of medicare part d on disparity implications of medication therapy management eligibility criteria.
    Wang J; Qiao Y; Shih YC; Jamison JJ; Spivey CA; Li L; Wan JY; White-Means SI; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
    Am Health Drug Benefits; 2014 Sep; 7(6):346-58. PubMed ID: 25558303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Socioeconomic and Geographical Characteristics of Beneficiaries Receiving a Comprehensive Medication Review.
    Chou J; Pellegrin K; Cooke CE; Zarowitz B; Hanlon A; Lozano A; Brandt NJ
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1276-1281. PubMed ID: 32996388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.
    Browning J; Tsang CCS; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Dong X; Wang J
    J Am Pharm Assoc (2003); 2022; 62(1):142-149. PubMed ID: 34509379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.
    Dong X; Tsang CCS; Zhao S; Wan JY; Shih YT; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Hines LE; Wang J
    Am Health Drug Benefits; 2021 Sep; 14(3):101-109. PubMed ID: 35261713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
    Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
    J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.